In an open label phase 2a clinical trial involving patients with biopsy proven NAFLD with elevated aminotransferases, participants received treatment with cysteamine bitartrate for six months and result showed marked decline in ALT and AST levels in all patients as well as significant decrease in cytokeratin and increase in adiponectin levels [181]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.